FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225417656> ?p ?o ?g. }

• W4225417656 abstract "Immunoglobulin light chain amyloidosis is a rare, multisystemic, phenotypically heterogenous disease affecting cardiovascular, renal, neurological, and gastrointestinal systems to varying degrees. Its underlying cause is a plasma cell dyscrasia characterized by misfolding of monoclonal immunoglobulin light chains which leads to aggregation and deposition of insoluble amyloid fibrils in target organs. Prognosis is primarily dependent on extent of cardiac involvement and depth of hematologic response to treatment. To facilitate development of new therapies, a public-private partnership was formed between the nonprofit Amyloidosis Research Consortium and the US Food and Drug Administration Center for Drug Evaluation and Research. In 2020, the Amyloidosis Forum launched an initiative to identify novel/composite end points and analytic strategies to expedite clinical trials for development of new therapies for the primary hematologic disorder and organ system manifestations. Specialized working groups identified organ-specific end points; additional working groups reviewed health-related quality of life measures and statistical approaches to data analysis. Each working group comprised amyloidosis experts, patient representatives, statisticians, and representatives from the Food and Drug Administration, the UK Medicines and Healthcare Products Regulatory Agency, and pharmaceutical companies. This review summarizes the proceedings and recommendations of the Cardiac Working Group. Using a modified Delphi method, the group identified, reviewed, and prioritized cardiac end points relevant to immunoglobulin light chain amyloidosis in the context of an antiplasma cell therapy. Prioritized cardiovascular end points included overall survival, hospitalization, N-terminal pro-B-type natriuretic peptide level, 6-minute walk test, Kansas City Cardiac Questionnaire, and cardiac deterioration progression-free survival. These recommended components will be further explored through evaluation of clinical trial datasets and formal guidance from regulatory authorities." @default.
• W4225417656 created "2022-05-05" @default.
• W4225417656 creator A5010445417 @default.
• W4225417656 creator A5011814572 @default.
• W4225417656 creator A5016624215 @default.
• W4225417656 creator A5027145476 @default.
• W4225417656 creator A5039428639 @default.
• W4225417656 creator A5044024465 @default.
• W4225417656 creator A5044879391 @default.
• W4225417656 creator A5057978794 @default.
• W4225417656 creator A5059417970 @default.
• W4225417656 creator A5085821633 @default.
• W4225417656 date "2022-06-01" @default.
• W4225417656 modified "2023-10-03" @default.
• W4225417656 title "Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group" @default.
• W4225417656 cites W1511191909 @default.
• W4225417656 cites W1769623626 @default.
• W4225417656 cites W1892471285 @default.
• W4225417656 cites W1956430368 @default.
• W4225417656 cites W1969551915 @default.
• W4225417656 cites W1973853538 @default.
• W4225417656 cites W2017006015 @default.
• W4225417656 cites W2017697017 @default.
• W4225417656 cites W2041574740 @default.
• W4225417656 cites W2043084865 @default.
• W4225417656 cites W2052620094 @default.
• W4225417656 cites W2061527271 @default.
• W4225417656 cites W2071522338 @default.
• W4225417656 cites W2100554882 @default.
• W4225417656 cites W2111080788 @default.
• W4225417656 cites W2114581617 @default.
• W4225417656 cites W2115902267 @default.
• W4225417656 cites W2126673903 @default.
• W4225417656 cites W2128583637 @default.
• W4225417656 cites W2148613212 @default.
• W4225417656 cites W2161231801 @default.
• W4225417656 cites W2168130167 @default.
• W4225417656 cites W2168507847 @default.
• W4225417656 cites W2171033052 @default.
• W4225417656 cites W2212004723 @default.
• W4225417656 cites W2217385909 @default.
• W4225417656 cites W2251254745 @default.
• W4225417656 cites W2298215063 @default.
• W4225417656 cites W2406569281 @default.
• W4225417656 cites W2461719883 @default.
• W4225417656 cites W2548150178 @default.
• W4225417656 cites W2597112130 @default.
• W4225417656 cites W2601316493 @default.
• W4225417656 cites W2604327713 @default.
• W4225417656 cites W2606253069 @default.
• W4225417656 cites W2606853863 @default.
• W4225417656 cites W2613202513 @default.
• W4225417656 cites W2613417438 @default.
• W4225417656 cites W2735511149 @default.
• W4225417656 cites W2749536631 @default.
• W4225417656 cites W2751712131 @default.
• W4225417656 cites W2772440046 @default.
• W4225417656 cites W2781851390 @default.
• W4225417656 cites W2790071297 @default.
• W4225417656 cites W2790265430 @default.
• W4225417656 cites W2886155385 @default.
• W4225417656 cites W2888036721 @default.
• W4225417656 cites W2898144881 @default.
• W4225417656 cites W2899144895 @default.
• W4225417656 cites W2912124608 @default.
• W4225417656 cites W2914577743 @default.
• W4225417656 cites W2946446637 @default.
• W4225417656 cites W2963531513 @default.
• W4225417656 cites W2971294569 @default.
• W4225417656 cites W2972956013 @default.
• W4225417656 cites W2977735554 @default.
• W4225417656 cites W2981001774 @default.
• W4225417656 cites W3016121819 @default.
• W4225417656 cites W3037159462 @default.
• W4225417656 cites W3038459712 @default.
• W4225417656 cites W3046813586 @default.
• W4225417656 cites W3089505857 @default.
• W4225417656 cites W3096317001 @default.
• W4225417656 cites W3096475516 @default.
• W4225417656 cites W3097146680 @default.
• W4225417656 cites W3097577984 @default.
• W4225417656 cites W3101841892 @default.
• W4225417656 cites W3102518094 @default.
• W4225417656 cites W3117028552 @default.
• W4225417656 cites W3128013154 @default.
• W4225417656 cites W3134745397 @default.
• W4225417656 cites W3135187698 @default.
• W4225417656 cites W3165948572 @default.
• W4225417656 cites W4205498725 @default.
• W4225417656 cites W4226367025 @default.
• W4225417656 cites W4245666729 @default.
• W4225417656 cites W4246147341 @default.
• W4225417656 cites W4292024189 @default.
• W4225417656 doi "https://doi.org/10.1161/circheartfailure.121.009038" @default.
• W4225417656 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35331001" @default.
• W4225417656 hasPublicationYear "2022" @default.
• W4225417656 type Work @default.
• W4225417656 citedByCount "5" @default.
• W4225417656 countsByYear W42254176562022 @default.
• W4225417656 countsByYear W42254176562023 @default.

• next